| Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study MJ Armstrong, P Gaunt, GP Aithal, D Barton, D Hull, R Parker, ... The Lancet 387 (10019), 679-690, 2016 | 2081 | 2016 |
| Lanreotide in metastatic enteropancreatic neuroendocrine tumors ME Caplin, M Pavel, JB Ćwikła, AT Phan, M Raderer, E Sedláčková, ... New England Journal of Medicine 371 (3), 224-233, 2014 | 2070 | 2014 |
| Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications GP Aithal, CP Day, PJL Kesteven, AK Daly The Lancet 353 (9154), 717-719, 1999 | 1715 | 1999 |
| HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ... Nature genetics 41 (7), 816-819, 2009 | 1201 | 2009 |
| Case definition and phenotype standardization in drug‐induced liver injury GP Aithal, PB Watkins, RJ Andrade, D Larrey, M Molokhia, H Takikawa, ... Clinical Pharmacology & Therapeutics 89 (6), 806-815, 2011 | 1193 | 2011 |
| Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening SA Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero ... Gastroenterology 150 (5), 1147-1159, 2016 | 1175 | 2016 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1165 | 2019 |
| Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers IN Guha, J Parkes, P Roderick, D Chattopadhyay, R Cross, S Harris, ... Hepatology 47 (2), 455-460, 2008 | 944 | 2008 |
| Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis GP Aithal, JA Thomas, PV Kaye, A Lawson, SD Ryder, I Spendlove, ... Gastroenterology 135 (4), 1176-1184, 2008 | 903 | 2008 |
| Guidelines on the management of ascites in cirrhosis KP Moore, GP Aithal Gut 55 (suppl 6), vi1-vi12, 2006 | 736 | 2006 |
| A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis SL Friedman, V Ratziu, SA Harrison, MF Abdelmalek, GP Aithal, ... Hepatology 67 (5), 1754-1767, 2018 | 734 | 2018 |
| TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease YL Liu, HL Reeves, AD Burt, D Tiniakos, S McPherson, JBS Leathart, ... Nature communications 5 (1), 4309, 2014 | 728 | 2014 |
| EASL clinical practice guidelines: drug-induced liver injury RJ Andrade, GP Aithal, ES Björnsson, N Kaplowitz, GA Kullak-Ublick, ... Journal of hepatology 70 (6), 1222-1261, 2019 | 711 | 2019 |
| Drug-induced liver injury RJ Andrade, N Chalasani, ES Björnsson, A Suzuki, GA Kullak-Ublick, ... Nature Reviews Disease Primers 5 (1), 58, 2019 | 635 | 2019 |
| Incidence and etiology of drug-induced liver injury in mainland China T Shen, Y Liu, J Shang, Q Xie, J Li, M Yan, J Xu, J Niu, J Liu, PB Watkins, ... Gastroenterology 156 (8), 2230-2241. e11, 2019 | 599 | 2019 |
| Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management V Ramappa, GP Aithal Journal of clinical and experimental hepatology 3 (1), 37-49, 2013 | 599 | 2013 |
| Drug-induced liver injury: recent advances in diagnosis and risk assessment GA Kullak-Ublick, RJ Andrade, M Merz, P End, A Benesic, AL Gerbes, ... Gut 66 (6), 1154-1164, 2017 | 539 | 2017 |
| Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles MI Lucena, M Molokhia, Y Shen, TJ Urban, GP Aithal, RJ Andrade, ... Gastroenterology 141 (1), 338-347, 2011 | 516 | 2011 |
| Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆ QM Anstee, R Darlay, S Cockell, M Meroni, O Govaere, D Tiniakos, ... Journal of hepatology 73 (3), 505-515, 2020 | 410 | 2020 |
| Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes AK Daly, GP Aithal, JBS Leathart, RA Swainsbury, TS Dang, CP Day Gastroenterology 132 (1), 272-281, 2007 | 405 | 2007 |
